{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["combination therapy", "drug discovery", "natural products", "osteosarcoma", "signaling pathway", "traditional medicinal plants"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35956961", "DateCompleted": {"Year": "2022", "Month": "08", "Day": "15"}, "DateRevised": {"Year": "2022", "Month": "08", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "08", "Day": "06"}], "Language": ["eng"], "ELocationID": ["5008", "10.3390/molecules27155008"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "15", "PubDate": {"Year": "2022", "Month": "Aug", "Day": "06"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Traditional Medicinal Plants as a Source of Inspiration for Osteosarcoma Therapy.", "Abstract": {"AbstractText": ["Osteosarcoma is one of the most common types of bone cancers among paediatric patients. Despite the advances made in surgery, chemo-, and radiotherapy, the mortality rate of metastatic osteosarcoma remains unchangeably high. The standard drug combination used to treat this bone cancer has remained the same for the last 20 years, and it produces many dangerous side effects. Through history, from ancient to modern times, nature has been a remarkable source of chemical diversity, used to alleviate human disease. The application of modern scientific technology to the study of natural products has identified many specific molecules with anti-cancer properties. This review describes the latest discovered anti-cancer compounds extracted from traditional medicinal plants, with a focus on osteosarcoma research, and on their cellular and molecular mechanisms of action. The presented compounds have proven to kill osteosarcoma cells by interfering with different pathways: apoptosis induction, stimulation of autophagy, generation of reactive oxygen species, etc. This wide variety of cellular targets confer natural products the potential to be used as chemotherapeutic drugs, and also the ability to act as sensitizers in drug combination treatments. The major hindrance for these molecules is low bioavailability. A problem that may be solved by chemical modification or nano-encapsulation."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 M\u00e1laga, Spain."}], "LastName": "Kazantseva", "ForeName": "Liliya", "Initials": "L"}, {"Identifier": ["0000-0002-4849-8931"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 M\u00e1laga, Spain."}, {"Identifier": [], "Affiliation": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Bioingenier\u00eda, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain."}, {"Identifier": [], "Affiliation": "Department of Cell Biology, Genetics and Physiology, Universidad de M\u00e1laga, 29071 M\u00e1laga, Spain."}], "LastName": "Becerra", "ForeName": "Jos\u00e9", "Initials": "J"}, {"Identifier": ["0000-0001-6159-6045"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, 29590 M\u00e1laga, Spain."}, {"Identifier": [], "Affiliation": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Bioingenier\u00eda, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 28029 Madrid, Spain."}, {"Identifier": [], "Affiliation": "Department of Cell Biology, Genetics and Physiology, Universidad de M\u00e1laga, 29071 M\u00e1laga, Spain."}], "LastName": "Santos-Ruiz", "ForeName": "Leonor", "Initials": "L"}], "GrantList": [{"GrantID": "713721", "Agency": "European Union's Horizon 2020 Research and Innovation Program - Marie Sklovodska-Curie", "Country": ""}, {"GrantID": "BIO2015-66266-R", "Agency": "Ministry of Economy, Industry and Competitiveness", "Country": ""}, {"GrantID": "RD16/0011/0022", "Agency": "Instituto de Salud Carlos III", "Country": ""}, {"GrantID": "CB06/06/1015", "Agency": "Consorcio Centro de Investigaci\u00f3n Biom\u00e9dica en Red", "Country": ""}, {"GrantID": "PI-0555-2013", "Agency": "Consejer\u00eda de Salud y Familias", "Country": ""}, {"GrantID": "PI-0032-2016", "Agency": "Consejer\u00eda de Salud y Familias", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Biological Products"}, {"RegistryNumber": "0", "NameOfSubstance": "Reactive Oxygen Species"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Apoptosis"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Biological Products"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Bone Neoplasms"}, {"QualifierName": [], "DescriptorName": "Child"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "pathology"], "DescriptorName": "Osteosarcoma"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Reactive Oxygen Species"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ottaviani G., Jaffe N. The Epidemiology of Osteosarcoma. Cancer Treat Res. 2009;152:3\u201313.", "ArticleIdList": ["20213383"]}, {"Citation": "Mirabello L., Troisi R.J., Savage S.A. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int. J. Cancer. 2009;125:229\u2013234. doi: 10.1002/ijc.24320.", "ArticleIdList": ["10.1002/ijc.24320", "PMC3048853", "19330840"]}, {"Citation": "Misaghi A., Goldin A., Awad M., Kulidjian A.A. Osteosarcoma: A comprehensive review. SICOT-J. 2018;4:12. doi: 10.1051/sicotj/2017028.", "ArticleIdList": ["10.1051/sicotj/2017028", "PMC5890448", "29629690"]}, {"Citation": "Durfee R.A., Mohammed M., Luu H.H. Review of Osteosarcoma and Current Management. Rheumatol. Ther. 2016;3:221\u2013243. doi: 10.1007/s40744-016-0046-y.", "ArticleIdList": ["10.1007/s40744-016-0046-y", "PMC5127970", "27761754"]}, {"Citation": "Kansara M., Teng M., Smyth M., Thomas D. Translational biology of osteosarcoma. Nat. Cancer. 2014;14:722\u2013735. doi: 10.1038/nrc3838.", "ArticleIdList": ["10.1038/nrc3838", "25319867"]}, {"Citation": "Hansen M.F., Seton M., Merchant A. Osteosarcoma in Paget\u2019s Disease of Bone. J. Bone Miner. Res. 2006;21:58\u201363. doi: 10.1359/jbmr.06s211.", "ArticleIdList": ["10.1359/jbmr.06s211", "17229010"]}, {"Citation": "Deyrup A.T., Montag A.G., Inwards C.Y., Xu M.Z., Swee R.G., Unni K.K. Sarcomas Arising in Paget Disease of Bone: A Clinicopathologic Analysis of 70 Cases. Arch. Pathol. Lab. Med. 2007;131:942\u2013946. doi: 10.5858/2007-131-942-SAIPDO.", "ArticleIdList": ["10.5858/2007-131-942-SAIPDO", "17550323"]}, {"Citation": "Huang M., Lu J.-J., Ding J. Natural Products in Cancer Therapy: Past, Present and Future. Nat. Prod. Bioprospecting. 2021;11:5\u201313. doi: 10.1007/s13659-020-00293-7.", "ArticleIdList": ["10.1007/s13659-020-00293-7", "PMC7933288", "33389713"]}, {"Citation": "Eder J., Sedrani R., Wiesmann C. The discovery of first-in-class drugs: Origins and evolution. Nat. Rev. Drug Discov. 2014;13:577\u2013587. doi: 10.1038/nrd4336.", "ArticleIdList": ["10.1038/nrd4336", "25033734"]}, {"Citation": "Madariaga-Maz\u00f3n A., Naveja J.J., Medina-Franco J.L., Noriega-Colima K.O., Martinez-Mayorga K. DiaNat-DB: A molecular database of antidiabetic compounds from medicinal plants. RSC Adv. 2021;11:5172\u20135178. doi: 10.1039/D0RA10453A.", "ArticleIdList": ["10.1039/D0RA10453A", "PMC8694643", "35424427"]}, {"Citation": "Paul D., Sanap G., Shenoy S., Kalyane D., Kalia K., Tekade R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today. 2021;26:80\u201393. doi: 10.1016/j.drudis.2020.10.010.", "ArticleIdList": ["10.1016/j.drudis.2020.10.010", "PMC7577280", "33099022"]}, {"Citation": "Ko\u017ami\u0144ski P., Halik P.K., Chesori R., Gniazdowska E. Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers. Int. J. Mol. Sci. 2020;21:3483. doi: 10.3390/ijms21103483.", "ArticleIdList": ["10.3390/ijms21103483", "PMC7279024", "32423175"]}, {"Citation": "Gonz\u00e1lez-Fern\u00e1ndez Y., Imbuluzqueta E., Zalacain M., Mollinedo F., Pati\u00f1o-Garc\u00eda A., Blanco-Prieto M.J. Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells. Cancer Lett. 2017;388:262\u2013268. doi: 10.1016/j.canlet.2016.12.012.", "ArticleIdList": ["10.1016/j.canlet.2016.12.012", "27998763"]}, {"Citation": "Yang F., Teves S.S., Kemp C.J., Henikoff S. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta. 2014;1845:84\u201389. doi: 10.1016/j.bbcan.2013.12.002.", "ArticleIdList": ["10.1016/j.bbcan.2013.12.002", "PMC3927826", "24361676"]}, {"Citation": "Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364\u2013378. doi: 10.1016/j.ejphar.2014.07.025.", "ArticleIdList": ["10.1016/j.ejphar.2014.07.025", "PMC4146684", "25058905"]}, {"Citation": "Chen B., Yang J.-Z., Wang L.-F., Zhang Y.-J., Lin X.-J. Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. BMC Cancer. 2015;15:752. doi: 10.1186/s12885-015-1735-6.", "ArticleIdList": ["10.1186/s12885-015-1735-6", "PMC4618398", "26486165"]}, {"Citation": "Mulder R.L., Paulides M., Langer T., Kremer L.C., van Dalen E.C. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane Database Syst. Rev. 2015;2015:CD006300. doi: 10.1002/14651858.CD006300.pub4.", "ArticleIdList": ["10.1002/14651858.CD006300.pub4", "PMC7389335", "26421585"]}, {"Citation": "Chamberlin S.R., Blucher A., Wu G., Shinto L., Choonoo G., Kulesz-Martin M., McWeeney S. Natural Product Target Network Reveals Potential for Cancer Combination Therapies. Front. Pharmacol. 2019;10:557. doi: 10.3389/fphar.2019.00557.", "ArticleIdList": ["10.3389/fphar.2019.00557", "PMC6555193", "31214023"]}, {"Citation": "Frank J.D., Barton S.J., Angelo J.M. Antineoplastic Drugs. In: Kwok I.K.K., Vincent E.C., Gibson J.N., editors. Pharmacology and Therapeutics for Dentistry. Elsevier Inc.; Mosby, Norway: 2017. pp. 530\u2013562."}, {"Citation": "Thirumaran R., Prendergast G.C., Gilman P.B. Cytotoxic Chemotherapy in Clinical Treatment of Cancer. In: Prendergast G.C., Jaffee E.M., editors. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Elsevier Inc.; Burlington, VT, USA: San Diego, CA, USA: London, UK: 2007. pp. 101\u2013116."}, {"Citation": "Birjees M., Ahmad M., Zafar M., Nawaz S., Jehanzeb S., Ullah F., Zaman W. Traditional knowledge of wild medicinal plants used by the inhabitants of Garam Chashma valley, district Chitral, Pakistan. Acta Ecol. Sin. 2022;42:19\u201333. doi: 10.1016/j.chnaes.2020.12.006.", "ArticleIdList": ["10.1016/j.chnaes.2020.12.006"]}, {"Citation": "Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Front. Pharmacol. 2014;4:177. doi: 10.3389/fphar.2013.00177.", "ArticleIdList": ["10.3389/fphar.2013.00177", "PMC3887317", "24454289"]}, {"Citation": "Haque I., Chowdhury A.B.M., Shahjahan M., Harun M., Dostogir G. Traditional healing practices in rural Bangladesh: A qualitative investigation. BMC Complement. Altern. Med. 2018;18:62. doi: 10.1186/s12906-018-2129-5.", "ArticleIdList": ["10.1186/s12906-018-2129-5", "PMC5815193", "29448941"]}, {"Citation": "Omara T., Kiprop A.K., Ramkat R.C., Cherutoi J., Kagoya S., Nyangena D.M., Tebo T.A., Nteziyaremye P., Karanja L.N., Jepchirchir A., et al. Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies. Evid.-Based Complement. Altern. Med. 2020;2020:3529081. doi: 10.1155/2020/3529081.", "ArticleIdList": ["10.1155/2020/3529081", "PMC7102457", "32256639"]}, {"Citation": "Kuruppu A.I., Paranagama P., Goonasekara C.L. Medicinal plants commonly used against cancer in traditional medicine formulae in Sri Lanka. Saudi Pharm. J. 2019;27:565\u2013573. doi: 10.1016/j.jsps.2019.02.004.", "ArticleIdList": ["10.1016/j.jsps.2019.02.004", "PMC6488922", "31061626"]}, {"Citation": "Cole C., Burgoyne T.W., Lee A., Stehno-Bittel L., Zaid G.H. Arum Palaestinum with isovanillin, linolenic acid and \u03b2-sitosterol inhibits prostate cancer spheroids and reduces the growth rate of prostate tumors in mice. BMC Complement. Altern. Med. 2015;15:264. doi: 10.1186/s12906-015-0774-5.", "ArticleIdList": ["10.1186/s12906-015-0774-5", "PMC4525741", "26243305"]}, {"Citation": "Abu-Darwish M.S., Efferth T. Medicinal Plants from Near East for Cancer Therapy. Front. Pharmacol. 2018;9:56. doi: 10.3389/fphar.2018.00056.", "ArticleIdList": ["10.3389/fphar.2018.00056", "PMC5797783", "29445343"]}, {"Citation": "Wang X.-H., Zhang S.-F., Bao J.-T., Liu F.-Y. Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins. Tumor Biol. 2017;39:1010428317701638. doi: 10.1177/1010428317701638.", "ArticleIdList": ["10.1177/1010428317701638", "28618955"]}, {"Citation": "Li X., Zhang C.-T., Ma W., Xie X., Huang Q. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Front. Pharmacol. 2021;12:645824. doi: 10.3389/fphar.2021.645824.", "ArticleIdList": ["10.3389/fphar.2021.645824", "PMC8289702", "34295243"]}, {"Citation": "Li J., Wu Y., Wang D., Zou L., Fu C., Zhang J., Leung G.P.-H. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. Pharmacol. Res. 2019;146:104313. doi: 10.1016/j.phrs.2019.104313.", "ArticleIdList": ["10.1016/j.phrs.2019.104313", "31202781"]}, {"Citation": "Wang Y., Zhu Z. Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway. Arch. Med Sci. 2019;15:1017\u20131027. doi: 10.5114/aoms.2018.77068.", "ArticleIdList": ["10.5114/aoms.2018.77068", "PMC6657258", "31360196"]}, {"Citation": "Yao Z., Xie F., Li M., Liang Z., Xu W., Yang J., Liu C., Li H., Zhou H., Qu L.-H. Oridonin induces autophagy via inhibition of glucose metabolism in p53-mutated colorectal cancer cells. Cell Death Dis. 2017;8:e2633. doi: 10.1038/cddis.2017.35.", "ArticleIdList": ["10.1038/cddis.2017.35", "PMC5386482", "28230866"]}, {"Citation": "Luo D., Yi Y., Peng K., Liu T., Yang J., Liu S., Zhao W., Qu X., Yu W., Gu Y., et al. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells. Eur. J. Med. Chem. 2019;178:365\u2013379. doi: 10.1016/j.ejmech.2019.06.006.", "ArticleIdList": ["10.1016/j.ejmech.2019.06.006", "31200238"]}, {"Citation": "Tian L., Xie K., Sheng D., Wan X., Zhu G. Antiangiogenic effects of oridonin. BMC Complement. Altern. Med. 2017;17:192. doi: 10.1186/s12906-017-1706-3.", "ArticleIdList": ["10.1186/s12906-017-1706-3", "PMC5379751", "28376864"]}, {"Citation": "Du Y., Zhang J., Yan S., Tao Z., Wang C., Huang M., Zhang X. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway. J. BUON. 2019;24:1175\u20131180.", "ArticleIdList": ["31424676"]}, {"Citation": "Lu Y., Sun Y., Zhu J., Yu L., Jiang X., Zhang J., Dong X., Ma B., Zhang Q. Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-\u03b3 and inhibiting Nrf2 pathway. Cell Death Dis. 2018;9:15. doi: 10.1038/s41419-017-0031-6.", "ArticleIdList": ["10.1038/s41419-017-0031-6", "PMC5849031", "29323103"]}, {"Citation": "Jin S., Shen J.-N., Wang J., Huang G., Zhou J.-G. Oridonin induced apoptosis through Akt and MAPKs signaling pathways in human osteosarcoma cells. Cancer Biol. Ther. 2007;6:261\u2013268. doi: 10.4161/cbt.6.2.3621.", "ArticleIdList": ["10.4161/cbt.6.2.3621", "17218775"]}, {"Citation": "Sun Y., Jiang X., Lu Y., Zhu J., Yu L., Ma B., Zhang Q. Oridonin prevents epithelial-mesenchymal transition and TGF-\u03b21-induced epithelial-mesenchymal transition by inhibiting TGF-\u03b21/Smad2/3 in osteosarcoma. Chem.-Biol. Interact. 2018;296:57\u201364. doi: 10.1016/j.cbi.2018.09.013.", "ArticleIdList": ["10.1016/j.cbi.2018.09.013", "30243739"]}, {"Citation": "Kazantseva L., Becerra J., Santos-Ruiz L. Oridonin enhances antitumor effects of doxorubicin in human osteosarcoma cells. Pharmacol. Rep. 2022;74:248\u2013256. doi: 10.1007/s43440-021-00324-1.", "ArticleIdList": ["10.1007/s43440-021-00324-1", "PMC8786785", "34427908"]}, {"Citation": "Zhang Y., Wang S., Dai M., Nai J., Zhu L., Sheng H. Solubility and Bioavailability Enhancement of Oridonin: A Review. Molecules. 2020;25:332. doi: 10.3390/molecules25020332.", "ArticleIdList": ["10.3390/molecules25020332", "PMC7024198", "31947574"]}, {"Citation": "Wang S.-Q., Wang C., Chang L.-M., Zhou K.-R., Wang J.-W., Ke Y., Yang D.-X., Shi H.-G., Wang R., Shi X.-L., et al. Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway. Oncotarget. 2016;7:72990\u201373002. doi: 10.18632/oncotarget.12166.", "ArticleIdList": ["10.18632/oncotarget.12166", "PMC5341958", "27659528"]}, {"Citation": "Liu X., Xu J., Zhou J., Shen Q. Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance. Genes Dis. 2020;8:448\u2013462. doi: 10.1016/j.gendis.2020.06.010.", "ArticleIdList": ["10.1016/j.gendis.2020.06.010", "PMC8209342", "34179309"]}, {"Citation": "Kimura Y., Sumiyoshi M. Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis. Phytomedicine. 2013;20:328\u2013336. doi: 10.1016/j.phymed.2012.10.016.", "ArticleIdList": ["10.1016/j.phymed.2012.10.016", "23219337"]}, {"Citation": "Chung J.-G., Lin C.-C., Kuo C.-L., Lee M.-H., Lai K.-C., Lin J.-P., Yang J.-S., Yu C.-S., Lu C.-C., Chiang J.-H., et al. Wogonin triggers apoptosis in human osteosarcoma U-2 OS cells through the endoplasmic reticulum stress, mitochondrial dysfunction and caspase-3-dependent signaling pathways. Int. J. Oncol. 2011;39:217\u2013224. doi: 10.3892/ijo.2011.1027.", "ArticleIdList": ["10.3892/ijo.2011.1027", "21573491"]}, {"Citation": "Ge Z., Ding S. The Crosstalk Between Tumor-Associated Macrophages (TAMs) and Tumor Cells and the Corresponding Targeted Therapy. Front. Oncol. 2020;10:590941. doi: 10.3389/fonc.2020.590941.", "ArticleIdList": ["10.3389/fonc.2020.590941", "PMC7670061", "33224886"]}, {"Citation": "Koh H., Sun H.-N., Xing Z., Liu R., Chandimali N., Kwon T., Lee D.-S. Wogonin Influences Osteosarcoma Stem Cell Stemness Through ROS-dependent Signaling. In Vivo. 2020;34:1077\u20131084. doi: 10.21873/invivo.11878.", "ArticleIdList": ["10.21873/invivo.11878", "PMC7279817", "32354895"]}, {"Citation": "Huynh D.L., Kwon T., Zhang J.J., Sharma N., Gera M., Ghosh M., Kim N., Cho S.K., Lee D.S., Park Y.H., et al. Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metallopeptidase-9 expression. BMC Complement. Altern. Med. 2017;17:304. doi: 10.1186/s12906-017-1788-y.", "ArticleIdList": ["10.1186/s12906-017-1788-y", "PMC5468967", "28606135"]}, {"Citation": "Gioti K., Papachristodoulou A., Benaki D., Aligiannis N., Skaltsounis A.-L., Mikros E., Tenta R. Assessment of the Nutraceutical Effects of Oleuropein and the Cytotoxic Effects of Adriamycin, When Administered Alone and in Combination, in MG-63 Human Osteosarcoma Cells. Nutrients. 2021;13:354. doi: 10.3390/nu13020354.", "ArticleIdList": ["10.3390/nu13020354", "PMC7911555", "33503913"]}, {"Citation": "Flemmig J., Kuchta K., Arnhold J., Rauwald H. Olea europaea leaf (Ph.Eur.) extract as well as several of its isolated phenolics inhibit the gout-related enzyme xanthine oxidase. Phytomedicine. 2011;18:561\u2013566. doi: 10.1016/j.phymed.2010.10.021.", "ArticleIdList": ["10.1016/j.phymed.2010.10.021", "21144719"]}, {"Citation": "Haloui E., Marzouk Z., Marzouk B., Bouftira I., Bouraoui A., Fenina N. Pharmacological activities and chemical composition of the Olea europaea L. leaf essential oils from Tunisia. J. Food Agric. Environ. 2010;8:204\u2013208."}, {"Citation": "Esmaeili-Mahani S., Rezaeezadeh-Roukerd M., Esmaeilpour K., Abbasnejad M., Rasoulian B., Sheibani V., Kaeidi A., Hajializadeh Z. Olive (Olea europaea L.) leaf extract elicits antinociceptive activity, potentiates morphine analgesia and suppresses morphine hyperalgesia in rats. J. Ethnopharmacol. 2010;132:200\u2013205. doi: 10.1016/j.jep.2010.08.013.", "ArticleIdList": ["10.1016/j.jep.2010.08.013", "20713147"]}, {"Citation": "Goldsmith C.D., Bond D.R., Jankowski H., Weidenhofer J., Stathopoulos C.E., Roach P.D., Scarlett C.J. The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells. Int. J. Mol. Sci. 2018;19:1937. doi: 10.3390/ijms19071937.", "ArticleIdList": ["10.3390/ijms19071937", "PMC6073890", "30004416"]}, {"Citation": "Vanella L., Acquaviva R., Di Giacomo C., Sorrenti V., Galvano F., Santangelo R., Cardile V., Gangia S., D\u2019Orazio N., Abraham N.G. Antiproliferative effect of oleuropein in prostate cell lines. Int. J. Oncol. 2012;41:31\u201338. doi: 10.3892/ijo.2012.1428.", "ArticleIdList": ["10.3892/ijo.2012.1428", "22484302"]}, {"Citation": "Liu L., Ahn K.S., Shanmugam M.K., Wang H., Shen H., Arfuso F., Chinnathambi A., Alharbi S.A., Chang Y., Sethi G., et al. Oleuropein induces apoptosis via abrogating NF-\u03baB activation cascade in estrogen receptor\u2013negative breast cancer cells. J. Cell. Biochem. 2019;120:4504\u20134513. doi: 10.1002/jcb.27738.", "ArticleIdList": ["10.1002/jcb.27738", "30260018"]}, {"Citation": "Moran J.M., Leal-Hernandez O., Canal-Mac\u00edas M.L., Roncero-Martin R., Guerrero-Bonmatty R., Aliaga I., Zamorano J.D.P. Antiproliferative Properties of Oleuropein in Human Osteosarcoma Cells. Nat. Prod. Commun. 2016;11:491\u2013492.", "ArticleIdList": ["27396201"]}, {"Citation": "Przychodzen P., Wyszkowska R., Gorzynik-Debicka M., Kostrzewa T., Kuban-Jankowska A., Gorska-Ponikowska M. Anticancer Potential of Oleuropein, the Polyphenol of Olive Oil, With 2-Methoxyestradiol, Separately or in Combination, in Human Osteosarcoma Cells. Anticancer Res. 2019;39:1243\u20131251. doi: 10.21873/anticanres.13234.", "ArticleIdList": ["10.21873/anticanres.13234", "30842154"]}, {"Citation": "Tian K.-M., Li J.-J., Xu S.-W. Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu) Pharmacol. Res. 2019;141:541\u2013550. doi: 10.1016/j.phrs.2018.12.019.", "ArticleIdList": ["10.1016/j.phrs.2018.12.019", "30616017"]}, {"Citation": "Jiang J., Hu C. Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa. Molecules. 2009;14:1852\u20131859. doi: 10.3390/molecules14051852.", "ArticleIdList": ["10.3390/molecules14051852", "PMC6254303", "19471205"]}, {"Citation": "Yang S., Chen J., Tan T., Wang N., Huang Y., Wang Y., Yuan X., Zhang P., Luo J., Luo X. Evodiamine Exerts Anticancer Effects Against 143B and MG63 Cells Through the Wnt/\u03b2-Catenin Signaling Pathway. Cancer Manag. Res. 2020;12:2875\u20132888. doi: 10.2147/CMAR.S238093.", "ArticleIdList": ["10.2147/CMAR.S238093", "PMC7196244", "32425601"]}, {"Citation": "Bai X., Meng H., Ma L., Guo A. Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis. Oncol. Lett. 2015;9:801\u2013805. doi: 10.3892/ol.2014.2791.", "ArticleIdList": ["10.3892/ol.2014.2791", "PMC4301500", "25621054"]}, {"Citation": "Meng Z.-J., Wu N., Liu Y., Shu K.-J., Zou X., Zhang R.-X., Pi C.-J., He B.-C., Ke Z.-Y., Chen L., et al. Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling. Oncol. Rep. 2015;34:1388\u20131396. doi: 10.3892/or.2015.4084.", "ArticleIdList": ["10.3892/or.2015.4084", "26135006"]}, {"Citation": "Sun G., Zhang C., Song H., Guo J., Li M., Cao Y. WZY-321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy-associated manner. Oncol. Lett. 2019;17:2465\u20132472. doi: 10.3892/ol.2018.9847.", "ArticleIdList": ["10.3892/ol.2018.9847", "PMC6341813", "30675312"]}, {"Citation": "Kan S.-F., Yu C.-H., Pu H.-F., Hsu J.-M., Chen M.-J., Wang P.S. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J. Cell. Biochem. 2007;101:44\u201356. doi: 10.1002/jcb.21036.", "ArticleIdList": ["10.1002/jcb.21036", "17340628"]}, {"Citation": "Pareek A., Suthar M., Rathore G.S., Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn. Rev. 2011;5:103\u2013110. doi: 10.4103/0973-7847.79105.", "ArticleIdList": ["10.4103/0973-7847.79105", "PMC3210009", "22096324"]}, {"Citation": "Knight D.W. Feverfew: Chemistry and biological activity. Nat. Prod. Rep. 1995;12:271\u2013276. doi: 10.1039/np9951200271.", "ArticleIdList": ["10.1039/np9951200271", "7792073"]}, {"Citation": "Nakshatri H., Rice S.E., Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene. 2004;23:7330\u20137344. doi: 10.1038/sj.onc.1207995.", "ArticleIdList": ["10.1038/sj.onc.1207995", "15286701"]}, {"Citation": "Kim S.L., Liu Y.C., Seo S.Y., Kim S.H., Kim I.H., Lee S.O., Lee S.T., Kim D.-G., Kim S.W. Parthenolide induces apoptosis in colitis-associated colon cancer, inhibiting NF-\u03baB signaling. Oncol. Lett. 2015;9:2135\u20132142. doi: 10.3892/ol.2015.3017.", "ArticleIdList": ["10.3892/ol.2015.3017", "PMC4467311", "26137027"]}, {"Citation": "Sun Y., Clair D.K.S., Xu Y., Crooks P.A., Clair W.H.S. A NADPH Oxidase\u2013Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer Cells. Cancer Res. 2010;70:2880\u20132890. doi: 10.1158/0008-5472.CAN-09-4572.", "ArticleIdList": ["10.1158/0008-5472.CAN-09-4572", "PMC2848907", "20233868"]}, {"Citation": "Vazhappilly C.G., Kumar D., Kumar R. Relative In Vitro Potentials of Parthenolide to Induce Apoptosis and Cell Cycle Arrest in Skin Cancer Cells. Curr. Drug Discov. Technol. 2016;13:34\u201340. doi: 10.2174/1570163813666160224124029.", "ArticleIdList": ["10.2174/1570163813666160224124029", "26906908"]}, {"Citation": "Zuch D., Giang A.-H., Shapovalov Y., Schwarz E., Rosier R., O\u2019Keefe R., Eliseev R.A. Targeting Radioresistant Osteosarcoma Cells With Parthenolide. J. Cell. Biochem. 2012;113:1282\u20131291. doi: 10.1002/jcb.24002.", "ArticleIdList": ["10.1002/jcb.24002", "PMC3307851", "22109788"]}, {"Citation": "Gong T., Su X., Xia Q., Wang J., Kan S. Expression of NF-\u03baB and PTEN in osteosarcoma and its clinical significance. Oncol. Lett. 2017;14:6744\u20136748. doi: 10.3892/ol.2017.6972.", "ArticleIdList": ["10.3892/ol.2017.6972", "PMC5678349", "29151913"]}, {"Citation": "Kishida Y., Yoshikawa H., Myoui A., Seliger B., Fedorushchenko A., Brenner W., Ackermann A., Atkins D., Hanash S., Lichtenfels R. Parthenolide, a Natural Inhibitor of Nuclear Factor-\u03baB, Inhibits Lung Colonization of Murine Osteosarcoma Cells. Clin. Cancer Res. 2007;13:59\u201367. doi: 10.1158/1078-0432.CCR-06-1559.", "ArticleIdList": ["10.1158/1078-0432.CCR-06-1559", "17200339"]}, {"Citation": "Dhanasekaran D.N., Reddy E.P. JNK-signaling: A multiplexing hub in programmed cell death. Genes Cancer. 2017;8:682\u2013694. doi: 10.18632/genesandcancer.155.", "ArticleIdList": ["10.18632/genesandcancer.155", "PMC5724802", "29234486"]}, {"Citation": "Yang C., Yang Q.O., Kong Q.-J., Yuan W., Yang Y.-P.O. Parthenolide Induces Reactive Oxygen Species-Mediated Autophagic Cell Death in Human Osteosarcoma Cells. Cell. Physiol. Biochem. 2016;40:146\u2013154. doi: 10.1159/000452532.", "ArticleIdList": ["10.1159/000452532", "27855364"]}, {"Citation": "D\u2019Anneo A., Carlisi D., Lauricella M., Emanuele S., Di Fiore R., Vento R., Tesoriere G. Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells. J. Cell. Physiol. 2013;228:952\u2013967. doi: 10.1002/jcp.24131.", "ArticleIdList": ["10.1002/jcp.24131", "22688575"]}, {"Citation": "Schwarz R., Bruland O., Cassoni A., Schomberg P., Bielack S. The Role of Radiotherapy in Oseosarcoma. Cancer Treat. Res. 2009;152:147\u2013164. doi: 10.1007/978-1-4419-0284-9_7.", "ArticleIdList": ["10.1007/978-1-4419-0284-9_7", "20213389"]}, {"Citation": "Mahajan A., Woo S.Y., Kornguth D.G., Hughes D., Huh W., Chang E.L., Herzog C.E., Pelloski C.E., Anderson P. Multimodality treatment of osteosarcoma: Radiation in a high-risk cohort. Pediatr. Blood Cancer. 2008;50:976\u2013982. doi: 10.1002/pbc.21451.", "ArticleIdList": ["10.1002/pbc.21451", "18213710"]}, {"Citation": "Sugiyasu K., Nanno K., Tamai N., Hashimoto N., Kishida Y., Yoshikawa H., Myoui A. Radio-sensitization of the murine osteosarcoma cell line LM8 with parthenolide, a natural inhibitor of NF-\u03baB. Oncol. Lett. 2011;2:407\u2013412. doi: 10.3892/ol.2011.277.", "ArticleIdList": ["10.3892/ol.2011.277", "PMC3410451", "22866095"]}, {"Citation": "Chang I.-C., Huang Y.-J., Chiang T.-I., Yeh C.-W., Hsu L.-S. Shikonin Induces Apoptosis through Reactive Oxygen Species/Extracellular Signal-Regulated Kinase Pathway in Osteosarcoma Cells. Biol. Pharm. Bull. 2010;33:816\u2013824. doi: 10.1248/bpb.33.816.", "ArticleIdList": ["10.1248/bpb.33.816", "20460760"]}, {"Citation": "Kong W.-Y., Chen X.-F., Shi J., Baloch S.K., Qi J.-L., Zhu H.-L., Wang X.-M., Yang Y.-H. Design and Synthesis of Fluoroacylshikonin as an Anticancer Agent. Chirality. 2013;25:757\u2013762. doi: 10.1002/chir.22209.", "ArticleIdList": ["10.1002/chir.22209", "23908135"]}, {"Citation": "Fu Z., Deng B., Liao Y., Shan L., Yin F., Wang Z., Zeng H., Zuo D., Hua Y., Cai Z. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer. 2013;13:580. doi: 10.1186/1471-2407-13-580.", "ArticleIdList": ["10.1186/1471-2407-13-580", "PMC4028842", "24314238"]}, {"Citation": "Deng B., Feng Y., Deng B. TIPE2 Mediates the Suppressive Effects of Shikonin on MMP13 in Osteosarcoma Cells. Cell. Physiol. Biochem. 2015;37:2434\u20132443. doi: 10.1159/000438596.", "ArticleIdList": ["10.1159/000438596", "26650545"]}, {"Citation": "Deng B., Qiu B. Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression. Tumor Biol. 2015;36:9311\u20139317. doi: 10.1007/s13277-015-3662-1.", "ArticleIdList": ["10.1007/s13277-015-3662-1", "26104765"]}, {"Citation": "Yang Q., Li S., Fu Z., Lin B., Zhou Z., Wang Z., Hua Y., Cai Z. Shikonin promotes adriamycin-induced apoptosis by upregulating caspase-3 and caspase-8 in osteosarcoma. Mol. Med. Rep. 2017;16:1347\u20131352. doi: 10.3892/mmr.2017.6729.", "ArticleIdList": ["10.3892/mmr.2017.6729", "PMC5562087", "28627658"]}, {"Citation": "Janeway K.A., Grier H.E. Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670\u2013678. doi: 10.1016/S1470-2045(10)70062-0.", "ArticleIdList": ["10.1016/S1470-2045(10)70062-0", "20347613"]}, {"Citation": "Liu Y., Zhang L., Song H., Ji G. Update on Berberine in Nonalcoholic Fatty Liver Disease. Evid.-Based Complement. Altern. Med. 2013;2013:1\u20138. doi: 10.1155/2013/308134.", "ArticleIdList": ["10.1155/2013/308134", "PMC3703418", "23843872"]}, {"Citation": "Mishra R., Nathani S., Varshney R., Sircar D., Roy P. Berberine reverses epithelial-mesenchymal transition and modulates histone methylation in osteosarcoma cells. Mol. Biol. Rep. 2020;47:8499\u20138511. doi: 10.1007/s11033-020-05892-8.", "ArticleIdList": ["10.1007/s11033-020-05892-8", "33074411"]}, {"Citation": "Liu J., Liu P., Xu T., Chen Z., Kong H., Chu W., Wang Y., Liu Y. Berberine Induces Autophagic Cell Death in Acute Lymphoblastic Leukemia by Inactivating AKT/mTORC1 Signaling. Drug Des. Dev. Ther. 2020;14:1813\u20131823. doi: 10.2147/DDDT.S239247.", "ArticleIdList": ["10.2147/DDDT.S239247", "PMC7229801", "32494123"]}, {"Citation": "Shen Z.-Q., Wang J., Tan W.-F., Huang T.-M. Berberine inhibits colorectal tumor growth by suppressing SHH secretion. Acta Pharmacol. Sin. 2021;42:1190\u20131194. doi: 10.1038/s41401-020-00514-2.", "ArticleIdList": ["10.1038/s41401-020-00514-2", "PMC8209003", "32958873"]}, {"Citation": "Lu W., DU S., Wang J. Berberine inhibits the proliferation of prostate cancer cells and induces G0/G1 or G2/M phase arrest at different concentrations. Mol. Med. Rep. 2015;11:3920\u20133924. doi: 10.3892/mmr.2014.3139.", "ArticleIdList": ["10.3892/mmr.2014.3139", "25572870"]}, {"Citation": "Sun Y., Wang W., Tong Y. Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin. Med Sci. Monit. 2019;25:9058\u20139066. doi: 10.12659/MSM.914486.", "ArticleIdList": ["10.12659/MSM.914486", "PMC6900918", "31779025"]}, {"Citation": "Jiang S.-X., Qi B., Yao W.-J., Gu C.-W., Wei X.-F., Zhao Y., Liu Y.-Z., Zhao B.-S. Berberine displays antitumor activity in esophageal cancer cells in vitro. World J. Gastroenterol. 2017;23:2511\u20132518. doi: 10.3748/wjg.v23.i14.2511.", "ArticleIdList": ["10.3748/wjg.v23.i14.2511", "PMC5394514", "28465635"]}, {"Citation": "Liu Z., Liu Q., Xu B., Wu J., Guo C., Zhu F., Yang Q., Gao G., Gong Y., Shao C. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat. Res. Mol. Mech. Mutagen. 2009;662:75\u201383. doi: 10.1016/j.mrfmmm.2008.12.009.", "ArticleIdList": ["10.1016/j.mrfmmm.2008.12.009", "19159633"]}, {"Citation": "Zhu Y., Ma N., Li H.-X., Tian L., Ba Y.-F., Hao B. Berberine induces apoptosis and DNA damage in MG-63 human osteosarcoma cells. Mol. Med. Rep. 2014;10:1734\u20131738. doi: 10.3892/mmr.2014.2405.", "ArticleIdList": ["10.3892/mmr.2014.2405", "PMC4148387", "25050485"]}, {"Citation": "Jin H., Jin X., Cao B., Wang W. Berberine affects osteosarcoma via downregulating the caspase-1/IL-1\u03b2 signaling axis. Oncol. Rep. 2017;37:729\u2013736. doi: 10.3892/or.2016.5327.", "ArticleIdList": ["10.3892/or.2016.5327", "PMC5355653", "28000894"]}, {"Citation": "Gao X., Zhang C., Wang Y., Zhang P., Zhang J., Hong T. Berberine and Cisplatin Exhibit Synergistic Anticancer Effects on Osteosarcoma MG-63 Cells by Inhibiting the MAPK Pathway. Molecules. 2021;26:1666. doi: 10.3390/molecules26061666.", "ArticleIdList": ["10.3390/molecules26061666", "PMC8002572", "33802664"]}, {"Citation": "Zhao X., Zhang Q., Chen L. Triptolide induces the cell apoptosis of osteosarcoma cells through the TRAIL pathway. Oncol. Rep. 2016;36:1499\u20131505. doi: 10.3892/or.2016.4957.", "ArticleIdList": ["10.3892/or.2016.4957", "27461934"]}, {"Citation": "He M.-F., Liu L., Ge W., Shaw P.-C., Jiang R., Wu L.-W., But P.P.-H. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J. Ethnopharmacol. 2009;121:61\u201368. doi: 10.1016/j.jep.2008.09.033.", "ArticleIdList": ["10.1016/j.jep.2008.09.033", "18996177"]}, {"Citation": "Phillips P.A., Dudeja V., McCarroll J.A., Borja-Cacho D., Dawra R.K., Grizzle W.E., Vickers S.M., Saluja A.K. Triptolide Induces Pancreatic Cancer Cell Death via Inhibition of Heat Shock Protein 70. Cancer Res. 2007;67:9407\u20139416. doi: 10.1158/0008-5472.CAN-07-1077.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-1077", "17909050"]}, {"Citation": "Li X., Zang A., Jia Y., Zhang J., Fan W., Feng J., Duan M., Zhang L., Huo R., Jiao J., et al. Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21. Mol. Med. Rep. 2016;13:2763\u20132768. doi: 10.3892/mmr.2016.4844.", "ArticleIdList": ["10.3892/mmr.2016.4844", "26847601"]}, {"Citation": "Wang H., Ma D., Wang C., Zhao S., Liu C. Triptolide Inhibits Invasion and Tumorigenesis of Hepatocellular Carcinoma MHCC-97H Cells Through NF-\u03baB Signaling. Med Sci. Monit. 2016;22:1827\u20131836. doi: 10.12659/MSM.898801.", "ArticleIdList": ["10.12659/MSM.898801", "PMC4920093", "27239780"]}, {"Citation": "Kwon H.-Y., Kim K.-S., An H.-K., Moon H.-I., Kim H.-J., Lee Y.-C. Triptolide induces apoptosis through extrinsic and intrinsic pathways in human osteosarcoma U2OS cells. Indian J. Biochem. Biophys. 2013;50:485\u2013491.", "ArticleIdList": ["24772972"]}, {"Citation": "Li X., Lu Q., Xie W., Wang Y., Wang G. Anti-tumor effects of triptolide on angiogenesis and cell apoptosis in osteosarcoma cells by inducing autophagy via repressing Wnt/\u03b2-Catenin signaling. Biochem. Biophys. Res. Commun. 2018;496:443\u2013449. doi: 10.1016/j.bbrc.2018.01.052.", "ArticleIdList": ["10.1016/j.bbrc.2018.01.052", "29330051"]}, {"Citation": "Qin W., Li S., Miao Y., Shi Q., Wang Y., Li J., Chen Z., Wang J., Ling C. Triptolide induces mitochondrial apoptosis through modulating dual specificity phosphatase 1/mitogen-activated protein kinases cascade in osteosarcoma cells. Neoplasma. 2018;65:21\u201333. doi: 10.4149/neo_2018_170109N16.", "ArticleIdList": ["10.4149/neo_2018_170109N16", "29322785"]}, {"Citation": "Zhao L., Jiang B., Wang D., Liu W., Zhang H., Liu W., Qiu Z. Triptolide reduces the viability of osteosarcoma cells by reducing MKP-1 and Hsp70 expression. Exp. Ther. Med. 2016;11:2005\u20132010. doi: 10.3892/etm.2016.3164.", "ArticleIdList": ["10.3892/etm.2016.3164", "PMC4840823", "27168842"]}, {"Citation": "Wang Z., Zhou J.-Y., Ma D.K., Buck S., Wu G.S., Mbbs Y.R. High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma. Pediatr. Blood Cancer. 2008;51:754\u2013759. doi: 10.1002/pbc.21727.", "ArticleIdList": ["10.1002/pbc.21727", "PMC2728603", "18726921"]}, {"Citation": "Jiang C., Fang X., Zhang H., Wang X., Li M., Jiang W., Tian F., Zhu L., Bian Z. AMD3100 combined with triptolide inhibit proliferation, invasion and metastasis and induce apoptosis of human U2OS osteosarcoma cells. Biomed. Pharmacother. 2017;86:677\u2013685. doi: 10.1016/j.biopha.2016.12.055.", "ArticleIdList": ["10.1016/j.biopha.2016.12.055", "28038429"]}, {"Citation": "Banerjee S., Thayanithy V., Sangwan V., Mackenzie T.N., Saluja A.K., Subramanian S. Minnelide reduces tumor burden in preclinical models of osteosarcoma. Cancer Lett. 2013;335:412\u2013420. doi: 10.1016/j.canlet.2013.02.050.", "ArticleIdList": ["10.1016/j.canlet.2013.02.050", "PMC4386634", "23499892"]}, {"Citation": "Hu N., Wang C., Dai X., Zhou M., Gong L., Yu L., Peng C., Li Y. Phillygenin inhibits LPS-induced activation and inflammation of LX2 cells by TLR4/MyD88/NF-\u03baB signaling pathway. J. Ethnopharmacol. 2020;248:112361. doi: 10.1016/j.jep.2019.112361.", "ArticleIdList": ["10.1016/j.jep.2019.112361", "31683033"]}, {"Citation": "Wu S., Zhang Y., Zhang Y., Chen L., Xu X., Dang Y., Ti X. Phillygenin regulates proliferation and apoptosis of non-small cell lung cancer through by AMPK/ERK/NF-\u03baB axis. Die Pharm.-Int. J. Pharm. Sci. 2020;75:512\u2013515. doi: 10.1691/ph.2020.0558.", "ArticleIdList": ["10.1691/ph.2020.0558", "33305728"]}, {"Citation": "Ding X., Lu D., Fan J. A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling. Biosci. Biotechnol. Biochem. 2021;85:307\u2013314. doi: 10.1093/bbb/zbaa007.", "ArticleIdList": ["10.1093/bbb/zbaa007", "33604629"]}, {"Citation": "Wei J., Chen J.-R., Pais E.M.A., Wang T.-Y., Miao L., Li L., Li L.-Y., Qiu F., Hu L.-M., Gao X.-M., et al. Oxyresveratrol Is a Phytoestrogen Exerting Anti-inflammatory Effects Through NF-\u03baB and Estrogen Receptor Signaling. Inflammation. 2017;40:1285\u20131296. doi: 10.1007/s10753-017-0572-y.", "ArticleIdList": ["10.1007/s10753-017-0572-y", "28484893"]}, {"Citation": "Rahman A., Bishayee K., Sadra A., Huh S.-O. Oxyresveratrol activates parallel apoptotic and autophagic cell death pathways in neuroblastoma cells. Biochim. Biophys. Acta Gen. Subj. 2017;1861:23\u201336. doi: 10.1016/j.bbagen.2016.10.025.", "ArticleIdList": ["10.1016/j.bbagen.2016.10.025", "27815218"]}, {"Citation": "Sunilkumar D., Drishya G., Chandrasekharan A., Shaji S.K., Bose C., Jossart J., Perry J.J.P., Mishra N., Kumar G.B., Nair B.G. Oxyresveratrol drives caspase-independent apoptosis-like cell death in MDA-MB-231 breast cancer cells through the induction of ROS. Biochem. Pharmacol. 2020;173:113724. doi: 10.1016/j.bcp.2019.113724.", "ArticleIdList": ["10.1016/j.bcp.2019.113724", "31756327"]}, {"Citation": "Liu Y., Ren W., Bai Y., Wan L., Sun X., Liu Y., Xiong W., Zhang Y.-Y., Zhou L. Oxyresveratrol prevents murine H22 hepatocellular carcinoma growth and lymph node metastasis via inhibiting tumor angiogenesis and lymphangiogenesis. J. Nat. Med. 2018;72:481\u2013492. doi: 10.1007/s11418-018-1173-2.", "ArticleIdList": ["10.1007/s11418-018-1173-2", "29350326"]}, {"Citation": "Lv T., Jian Z., Li D., Ao R., Zhang X., Yu B. Oxyresveratrol induces apoptosis and inhibits cell viability via inhibition of the STAT3 signaling pathway in Saos-2 cells. Mol. Med. Rep. 2020;22:5191\u20135198. doi: 10.3892/mmr.2020.11591.", "ArticleIdList": ["10.3892/mmr.2020.11591", "PMC7646976", "33174060"]}, {"Citation": "Calonghi N., Farruggia G., Boga C., Micheletti G., Fini E., Romani L., Telese D., Faraci E., Bergamini C., Cerini S., et al. Root Extracts of Two Cultivars of Paeonia Species: Lipid Composition and Biological Effects on Different Cell Lines: Preliminary Results. Molecules. 2021;26:655. doi: 10.3390/molecules26030655.", "ArticleIdList": ["10.3390/molecules26030655", "PMC7865396", "33513825"]}, {"Citation": "De Azevedo J.W.V., Fernandes T.A.A.D.M., Fernandes J.V., de Azevedo J.C.V., Lanza D.C.F., Bezerra C.M., Andrade V.S., de Araujo J.M.G. Biology and pathogenesis of human osteosarcoma. Oncol. Lett. 2020;19:1099\u20131116. doi: 10.3892/ol.2019.11229.", "ArticleIdList": ["10.3892/ol.2019.11229", "PMC6955653", "31966039"]}, {"Citation": "Park T.S., Donnenberg V.S., Donnenberg A.D., Zambidis E.T., Zimmerlin L. Dynamic Interactions Between Cancer Stem Cells and Their Stromal Partners. Curr. Pathobiol. Rep. 2014;2:41\u201352. doi: 10.1007/s40139-013-0036-5.", "ArticleIdList": ["10.1007/s40139-013-0036-5", "PMC3956651", "24660130"]}, {"Citation": "Carvalho C., Santos R.X., Cardoso S., Correia S., Oliveira P.J., Santos M.S., Moreira P.I. Doxorubicin: The Good, the Bad and the Ugly Effect. Curr. Med. Chem. 2009;16:3267\u20133285. doi: 10.2174/092986709788803312.", "ArticleIdList": ["10.2174/092986709788803312", "19548866"]}, {"Citation": "Pugazhendhi A., Edison T.N.J.I., Velmurugan B.K., Jacob J.A., Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26\u201330. doi: 10.1016/j.lfs.2018.03.023.", "ArticleIdList": ["10.1016/j.lfs.2018.03.023", "29534993"]}, {"Citation": "De Luca A., Raimondi L., Salamanna F., Carina V., Costa V., Bellavia D., Alessandro R., Fini M., Giavaresi G. Relevance of 3d culture systems to study osteosarcoma environment. J. Exp. Clin. Cancer Res. 2018;37:2. doi: 10.1186/s13046-017-0663-5.", "ArticleIdList": ["10.1186/s13046-017-0663-5", "PMC5756329", "29304852"]}, {"Citation": "Monteiro C.F., Cust\u00f3dio C.A., Mano J.F. Bioengineering a humanized 3D tri-culture osteosarcoma model to assess tumor invasiveness and therapy response. Acta Biomater. 2021;134:204\u2013214. doi: 10.1016/j.actbio.2021.07.034.", "ArticleIdList": ["10.1016/j.actbio.2021.07.034", "34303015"]}, {"Citation": "Dehelean C., Marcovici I., Soica C., Mioc M., Coricovac D., Iurciuc S., Cretu O., Pinzaru I. Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy. Molecules. 2021;26:1109. doi: 10.3390/molecules26041109.", "ArticleIdList": ["10.3390/molecules26041109", "PMC7922180", "33669817"]}, {"Citation": "Calonghi N., Boga C., Nitti P., Telese D., Bordoni S., Farruggia G., Asaro F., Grandi M., Zalambani C., Micheletti G. Effects of Regioisomerism on the Antiproliferative Activity of Hydroxystearic Acids on Human Cancer Cell Lines. Molecules. 2022;27:2396. doi: 10.3390/molecules27082396.", "ArticleIdList": ["10.3390/molecules27082396", "PMC9029951", "35458594"]}, {"Citation": "Puglia C., Lauro M.R., Tirendi G.G., Fassari G.E., Carbone C., Bonina F., Puglisi G. Modern drug delivery strategies applied to natural active compounds. Expert Opin. Drug Deliv. 2017;14:755\u2013768. doi: 10.1080/17425247.2017.1234452.", "ArticleIdList": ["10.1080/17425247.2017.1234452", "27606793"]}, {"Citation": "Khazei K., Mohajeri N., Bonabi E., Turk Z., Zarghami N. New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles. Curr. Cancer Drug Targets. 2021;21:689\u2013701. doi: 10.2174/1568009621666210525152802.", "ArticleIdList": ["10.2174/1568009621666210525152802", "34036921"]}, {"Citation": "Yin Q., Tang L., Cai K., Tong R., Sternberg R., Yang X., Dobrucki L.W., Borst L.B., Kamstock D., Song Z., et al. Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. Proc. Natl. Acad. Sci. USA. 2016;113:E4601\u2013E4609. doi: 10.1073/pnas.1603316113.", "ArticleIdList": ["10.1073/pnas.1603316113", "PMC4987772", "27457945"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "5"}, {"Year": "2022", "Month": "7", "Day": "28"}, {"Year": "2022", "Month": "7", "Day": "29"}, {"Year": "2022", "Month": "8", "Day": "12", "Hour": "1", "Minute": "20"}, {"Year": "2022", "Month": "8", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "8", "Day": "6"}], "PublicationStatus": "epublish", "ArticleIdList": ["35956961", "PMC9370649", "10.3390/molecules27155008", "molecules27155008"]}}], "PubmedBookArticle": []}